Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Antitumor activity of cepharanthine and tetrandrine for 2d and 3d culture of breast cancer cells

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: KIYOMI, Anna (Tokyo University of Pharmacy and Life Sciences, Drug Safety and Risk Management)
  • Co-author(s): Anna Kiyomi: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Risako Miyakawa: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Kyosuke Yamazaki: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Juri Matsumoto: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Yuki Nakajima: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Toshihiko Hirano: Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
    Munetoshi Sugiura: Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan
  • Abstract:

    Background

    Three-dimensional culture (3D) systems can mimic the in-vivo environment more precisely than 2D culture systems. While tetrandrine (TET), a bis-benzylisoquinoline alkaloid, has been reported for its anti-cancer activity, the effect on breast cancer of cepharanthine (CEP), a TET analog, having a long history of use and little toxicity,..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses